Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by ABE, O.
Right arrow Articles by YAMAMOTO, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by ABE, O.
Right arrow Articles by YAMAMOTO, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 3:99-104 (1973)
© 1973 Foundation for Promotion of Cancer Research

2{alpha} 3{alpha}-Epithio-5{alpha}-androstan-17ß-ol in Treatment of Gynecomastia

OSAHIKO ABE, M.D.1, SOICHI KUMAOKA, M.D.2 and HIROSHI YAMAMOTO, M.D.3

1 Department of Surgery, National Cancer Center Hospital Tokyo, Japan
2 Endocrinology Division, National Cancer Center Research Institute Tokyo, Japan
33 Department of Surgery, National Cancer Center Hospital Tokyo, Japan

Received November 19, 1973;

  1. 1. The clinical effect of epitiostanol, a new anti-estrogen agent (2{alpha},3{alpha}-epithio-5a-androstan-17ß-ol) against gynecomastia was studied in comparison with dromostanolone propionate in fifty-four patients ranging from twenty to fifty years in age without previous history of hormone therapy and with normal liver function. The experiment was performed for eight weeks by double blind methods in three dosage groups, epithiostanol 10 mg, and 20 mg and dromostanolone propionate 50 mg.
  2. 2. Epithiostanol 20 mg was most effective with regards to effect on mass size and tenderness, (effective in 96%, 20/21), followed by 10 mg epitiostanol (effective in 89%, 16/18) and dromostanolone propionate 50 mg (effective in 89%, 16/18) in descending order. No side effects were observed in any of the three groups.
  3. 3. Based on the results of the present study, epitiostanol is concluded to be at least as effective as dromostanolone propionate against gynecomastia and to be safe from the viewpoint of side effects. A satisfactory therapeutical effect on gynecomastia can be expected with a weekly dosage of 20 mg of epitiostanol for an administration period of between five to eight weeks.

Present Address: Department of Surgery, Keio University Hospital, Shinanomachi, Shin-juku-ku, Tokyo, Japan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.